TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Other EventsItem 8.01. Other Events.
On October 26, 2017, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results from the Phase 2 multicenter trial of TG-1101 (ublituximab) in relapsing forms of Multiple Sclerosis (RMS) presented during the 7th Joint ECTRIMS – ACTRIMS meeting in Paris, France. On October 27, 2017, the Company announced additional results from the Phase 2 multicenter trial of TG-1101 in RMS presented during the 7th Joint ECTRIMS – ACTRIMS meeting. Copies of the press releases are being filed as Exhibits 99.1 and 99.2 and incorporated in this Item by reference.
Item 9.01 Financial Statements And Exhibits.
(d) Exhibits.
99.1 Press Release, dated October 26, 2017.
99.2 Press Release, dated October 27, 2017.
TG THERAPEUTICS, INC. ExhibitEX-99.1 2 v102617_ex991.htm EXHIBIT 99.1 Blueprint TG Therapeutics,…To view the full exhibit click here
About TG Therapeutics, Inc. (NASDAQ:TGTX)
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.